Company intelligence / Profile preview
Shanghai Huaota Biopharmaceutical Co., Ltd.
Shanghai, Shanghai, Chinaplaneteveryone.net ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Multiple products in clinical development with HB-0017 (IL-17A inhibitor) in Phase 3 for psoriatic arthritis, Recibokibart (IL-36R inhibitor) in Phase 2/3 for generalized pustular psoriasis, HB002.1M (VEGF inhibitor) in Phase 2 for diabetic macular edema, and several other candidates in Phase 1/2 trials
- Therapeutic areas
- GastroenterologyPulmonologyRheumatologyOphthalmologyImmunologyDermatologyOncology
- Modalities
- Monoclonal antibodiesBispecific antibodiesFusion proteinsAntibody drug conjugates (ADC)Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Korea Eutilex Co., Ltd.US Oncobiologics Inc.Shanghai Junshi Biosciences Co., Ltd.
Beyond the preview
Go deeper on Shanghai Huaota Biopharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Huaota Biopharmaceutical Co., Ltd..